From Name

From Email

To Name

To Email

Message

With new proposal, Trump administration tries to encourage 'value-based' drug deals

from Healthcare Dive

With new proposal, Trump administration tries to encourage 'value-based' drug deals Healthcare Dive The Trump administration on Wednesday proposed changes to how drugmakers can report their prices to Medicaid, seeking to make it easier for pharmaceutical companies and insurers to enter into contracts that tie payment to patient outcomes. Typically, drug contracts are linked to the volume of product sold, providing for larger manufacturer rebates the more a product is prescribed and covered by an insurer. Increasingly, however, drugmakers and insurers have been exploring alternative approaches centered on some measure of a medicine's value. READ MORE

more